JAMA Network | JAMA Internal Medicine | Genotype-Guided vs Clinical Dosing of Warfarin and Its Analogues: Meta-analysis of Randomized Clinical Trials

JAMA Network | JAMA Internal Medicine | Genotype-Guided vs Clinical Dosing of Warfarin and Its Analogues:  Meta-analysis of Randomized Clinical Trials

Evidence-based Pharmacogenomics:

Genotype-guided vs clinical dosing of warfarin and its analogues
Stergiopoulos K, et al. JAMA Intern Med. June 16, 2014

Warfarin, genes, and the (health care) environment. 
Dhruv S. Kazi et al.  JAMA Internal Medicine, June 16, 2014. 

A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users. 
Ruben L. Osnabrugge et al. Genetics in Medicine, June 19, 2014

FDA table of pharmacogenomic markers includes drugs with genomic information in their labeling. The labeling for some, but not all, of the products includes specific actions to be taken based on the biomarker information.

CDC information: Several pharmacogenomic tests are tier 1 genomic applications.

CDC paper: Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.  Dotson WD, et al. Clin Pharmacol Ther. 2014 Apr;95(4):394-402.